PL2451771T3 - Sole rasagiliny i ich preparaty farmaceutyczne - Google Patents

Sole rasagiliny i ich preparaty farmaceutyczne

Info

Publication number
PL2451771T3
PL2451771T3 PL10731734T PL10731734T PL2451771T3 PL 2451771 T3 PL2451771 T3 PL 2451771T3 PL 10731734 T PL10731734 T PL 10731734T PL 10731734 T PL10731734 T PL 10731734T PL 2451771 T3 PL2451771 T3 PL 2451771T3
Authority
PL
Poland
Prior art keywords
rasagiline
salts
pharmaceutical preparations
preparations
pharmaceutical
Prior art date
Application number
PL10731734T
Other languages
English (en)
Inventor
Thomas Thyrann
Christian Janssen
Ramesh Matioram Gidwani
Original Assignee
Ratiopharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm Gmbh filed Critical Ratiopharm Gmbh
Publication of PL2451771T3 publication Critical patent/PL2451771T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/122Propionic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126Acids containing more than four carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03Monocarboxylic acids
    • C07C57/12Straight chain carboxylic acids containing eighteen carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
PL10731734T 2009-07-09 2010-07-07 Sole rasagiliny i ich preparaty farmaceutyczne PL2451771T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1632CH2009 2009-07-09
PCT/EP2010/059723 WO2011003938A1 (en) 2009-07-09 2010-07-07 Salts of rasagiline and pharmaceutical preparations thereof
EP10731734.9A EP2451771B1 (en) 2009-07-09 2010-07-07 Salts of rasagiline and pharmaceutical preparations thereof

Publications (1)

Publication Number Publication Date
PL2451771T3 true PL2451771T3 (pl) 2014-12-31

Family

ID=42634609

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10731734T PL2451771T3 (pl) 2009-07-09 2010-07-07 Sole rasagiliny i ich preparaty farmaceutyczne

Country Status (15)

Country Link
US (1) US8946482B2 (pl)
EP (1) EP2451771B1 (pl)
JP (1) JP2012532843A (pl)
AU (1) AU2010270254A1 (pl)
CA (1) CA2767592A1 (pl)
CY (1) CY1115595T1 (pl)
DK (1) DK2451771T3 (pl)
ES (1) ES2503015T3 (pl)
HR (1) HRP20140845T1 (pl)
IL (1) IL217239A0 (pl)
PL (1) PL2451771T3 (pl)
PT (1) PT2451771E (pl)
RS (1) RS53504B1 (pl)
SI (1) SI2451771T1 (pl)
WO (1) WO2011003938A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007217349B9 (en) 2006-02-21 2013-06-27 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Multiple System Atrophy
WO2007117431A2 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
EA016820B1 (ru) 2006-12-14 2012-07-30 Тева Фармасьютикал Индастриз, Лтд. Кристаллическое твердое основание разагилина
US8188149B2 (en) 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
EP2299993A4 (en) 2008-06-19 2014-08-20 Teva Pharma PROCESS FOR PURIFYING THE BASE OF RASAGILINE
CN102065853A (zh) 2008-06-19 2011-05-18 泰华制药工业有限公司 制备和干燥固体雷沙吉兰碱的方法
US20100189788A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
WO2011121607A2 (en) 2010-03-29 2011-10-06 Cadila Healthcare Limited Rasagiline and its pharmaceutically acceptable salts
US8569379B2 (en) 2010-07-27 2013-10-29 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
AU2011282716A1 (en) 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
HU231054B1 (hu) * 2010-11-18 2020-04-28 Egis Gyógyszergyár Nyrt. Gyógyászati készítmény előállítására alkalmazható új sók
EP2705021A2 (en) 2011-05-04 2014-03-12 Cadila Healthcare Limited Rasagiline and its pharmaceutically acceptable salts
CN103874487A (zh) 2011-10-10 2014-06-18 泰华制药工业有限公司 R(+)-n-甲酰-炔丙基-氨基茚满
MX2014004201A (es) 2011-10-10 2015-01-12 Teva Pharma R(+)-n-metil-propargil-aminoindano.
EP2884972A4 (en) 2012-08-17 2016-05-11 Teva Pharma PARENTERAL FORMULATION OF RASAGILINE
WO2014192022A1 (en) * 2013-05-20 2014-12-04 Cadila Healthcare Limited Pharmaceutical compositions of rasagiline
EP3079672B1 (en) * 2013-12-11 2020-05-13 KRKA, d.d., Novo mesto Pharmaceutical composition comprising a pharmaceutically acceptable salt of rasagiline
US20170197980A1 (en) * 2014-06-25 2017-07-13 Abbvie Inc. N-(4-phenyl)-n'-(3-fluorophenyl)urea docusate
CN111635305A (zh) * 2020-07-01 2020-09-08 中山华明泰科技股份有限公司 一种复合异辛酸锌制备方法及应用
CN116036055A (zh) * 2023-03-16 2023-05-02 上海世领制药有限公司 一种含甲磺酸雷沙吉兰的透皮贴剂及其制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3253037A (en) * 1962-06-19 1966-05-24 Ciba Geigy Corp N-2-alkynyl-amino-benzocylo-alkanes
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
JP4222632B2 (ja) 1996-12-18 2009-02-12 テバ・ファーマシューティカル・インダストリーズ・リミテッド アミノインダン誘導体
IL141690A (en) 2001-02-27 2004-06-20 Isp Finetech Ltd Process for preparation of rasagiline and its salts
DK1567152T3 (da) 2002-11-15 2013-10-07 Teva Pharma Anvendelse af rasagilin med riluzol til behandling af amyotroph lateral sklerose
CA2574925A1 (en) 2004-07-26 2006-02-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical dosage forms including rasagiline
US20090111892A1 (en) 2004-11-24 2009-04-30 Shulamit Patashnik Rasagiline Orally Disintegrating Compositions
NZ560660A (en) 2005-02-23 2010-11-26 Teva Pharma Rasagiline ( R(+)-N-propargyl-1-aminodan ) formulations of improved content uniformity
CA2630037C (en) 2005-11-17 2015-03-31 Teva Pharmaceutical Industries Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
AU2007217349B9 (en) 2006-02-21 2013-06-27 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Multiple System Atrophy
WO2007117431A2 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
EA016820B1 (ru) 2006-12-14 2012-07-30 Тева Фармасьютикал Индастриз, Лтд. Кристаллическое твердое основание разагилина
AU2007334493B2 (en) 2006-12-14 2010-12-02 Teva Pharmaceutical Industries, Ltd. Tannate salt of rasagiline
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
CA2698695A1 (en) 2007-09-05 2009-03-12 Teva Pharmaceutical Industries Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
KR20100107028A (ko) 2008-01-11 2010-10-04 테바 파마슈티컬 인더스트리즈 리미티드 라사길린 제형, 그들의 제법 및 용도
US20100008983A1 (en) 2008-06-10 2010-01-14 Muhammad Safadi Rasagiline soft gelatin capsules
JP2011522892A (ja) 2008-06-13 2011-08-04 テバ ファーマシューティカル インダストリーズ リミティド パーキンソン病緩和のためのラサギリン
CN102065853A (zh) 2008-06-19 2011-05-18 泰华制药工业有限公司 制备和干燥固体雷沙吉兰碱的方法
EP2299993A4 (en) 2008-06-19 2014-08-20 Teva Pharma PROCESS FOR PURIFYING THE BASE OF RASAGILINE
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189788A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
WO2011042812A1 (en) 2009-10-09 2011-04-14 Stefan Lorenzl Use of rasagiline for the treatment of progressive supranuclear palsy
CA2785501A1 (en) 2009-12-22 2011-07-21 Teva Pharmaceutical Industries Ltd. 3-keto-n-propargyl-1-aminoindan
US8569379B2 (en) 2010-07-27 2013-10-29 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
AU2011282716A1 (en) 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
CA2816104A1 (en) 2010-10-26 2012-05-03 Teva Pharmaceutical Industries Ltd. Deuterium enriched rasagiline
CN103874487A (zh) 2011-10-10 2014-06-18 泰华制药工业有限公司 R(+)-n-甲酰-炔丙基-氨基茚满
CA2851274A1 (en) 2011-10-10 2013-04-18 Konstantin Ulanenko Rasagiline citramide
MX2014004201A (es) 2011-10-10 2015-01-12 Teva Pharma R(+)-n-metil-propargil-aminoindano.

Also Published As

Publication number Publication date
WO2011003938A1 (en) 2011-01-13
AU2010270254A1 (en) 2012-02-02
US20120142966A1 (en) 2012-06-07
US8946482B2 (en) 2015-02-03
RS53504B1 (en) 2015-02-27
EP2451771B1 (en) 2014-06-18
EP2451771A1 (en) 2012-05-16
SI2451771T1 (sl) 2014-10-30
CA2767592A1 (en) 2011-01-13
ES2503015T3 (es) 2014-10-06
PT2451771E (pt) 2014-09-19
CY1115595T1 (el) 2017-01-04
DK2451771T3 (da) 2014-09-08
IL217239A0 (en) 2012-02-29
HRP20140845T1 (hr) 2014-11-07
JP2012532843A (ja) 2012-12-20

Similar Documents

Publication Publication Date Title
IL217239A0 (en) Salts of rasagiline and pharmaceutical preparations thereof
HK1255336A1 (zh) 藥物製劑及其製備方法
IL253870B (en) Certain amino-pyrimidines and pharmaceutical preparations containing them
IL226231B (en) A once-daily formulation of lacosamide
EP2358658A4 (en) PREPARATION OF RASAGILIN AND ITS SALTS
IL214402A0 (en) Transdermal pharmaceutical preparations
EP2548859A4 (en) PREPARATION OF METHYL-D3-AMINE AND SALTS THEREOF
HK1169379A1 (en) Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof 3-
EP2718283A4 (en) INDAZOLE AND PYRROLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
EP2402305A4 (en) LOXOPROFEN DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME
IL219155A0 (en) Pharmaceutical formulations of nitrite and uses thereof
EP2655410A4 (en) ANTI-INFLAMMATORY PROTEINS AND METHODS OF PREPARATION AND USE THEREOF
EP2470542A4 (en) PREPARATION OF SITAGLIPTIN AND SALTS THEREOF
HK1198939A1 (en) Pharmaceutical preparation comprising brexpiprazole and substituted beta - cyclodextrin brexpiprazole -
ZA201108458B (en) Nitrile derivatives and their pharmaceutical use and compositions
EP2398475A4 (en) PHARMACEUTICAL PREPARATION AND DISPOSAL SYSTEM
IL221087A (en) Pharmacy or nutritional composition
IL222714A0 (en) Preparation of polypeptides and salts thereof
PT2597084T (pt) Derivado de n-hidroxiformamida e medicamento contendo o mesmo
PL2654723T3 (pl) Stałe postacie leku zawierające tadalafil i sposoby ich otrzymywania
EP2452681A4 (en) SALTS OF 13A- (S-) DESOXYTYLPHORININE, METHOD FOR THE PRODUCTION THEREOF, AND PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF
HUP1000407A2 (en) Ph dependent pulsatile and sustained release pharmaceutical composition
GB0922537D0 (en) Pharmaceutical preparation
EP2668961A4 (en) PHARMACEUTICAL COMBINATION PREPARATION
GB201112578D0 (en) Pharmaceutical preparation and use